Navigation Links
Nucletron, an Elekta company, installs Esteya for treating skin cancer in major US center
Date:12/13/2013

NEW YORK, Dec. 13, 2013 /PRNewswire/ -- The first Esteya® electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.

"With support from Elekta, Memorial Sloan-Kettering will lead a multicenter clinical study with the goal to further improve skin cancer treatment," says John Lapre, Executive Vice President, Elekta Brachytherapy. "With its leading role at the forefront of brachytherapy research, the hospital will help advance the quality of patient care and add to the evidence base that caregivers need for their clinical decisions."

Esteya features an efficient workflow, easy patient set-up, and a short, less than three-minute, treatment delivery. The system's compact design and reduced shielding requirements also make treatment with Esteya highly accessible, enabling clinicians to treat lesions virtually anywhere patients are seen in the clinic.

For more information about Esteya, visit www.esteya.com.

Availability of Esteya in identified markets is subject to regulatory approvals.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nucletron, an Elekta Company, Receives U.S. FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer
2. Nucletron, an Elekta company, to Debut New Flexitron Brachytherapy Afterloading Platform at 2013 American Brachytherapy Society Meeting
3. Elekta receives US FDA 510(k) clearance for its Monaco 5 treatment planning system
4. Elekta opens state-of-the-art radiotherapy training center in Beijing
5. Elekta appoints Niklas Savander as its next President and Chief Executive Officer
6. Private Hospital Group in Spain Expands Radiotherapy Capabilities with Countrys First Elekta Versa HD System
7. Elekta Announces Monaco 5.0 -- Comprehensive Radiation Treatment Planning Capabilities Brought Together in One System
8. New Elekta Radiation Therapy Technology Takes Weeks Off of Lung Cancer Treatments
9. Switzerlands Hopital Riviera Improves Confidence in Patient Treatment with Elektas Identify Solution
10. Elekta to Spotlight Versa HD System at 2013 ASTRO Annual Meeting
11. Elekta Introduces Groundbreaking Image Guidance Capabilities Integrated with Versa HD Cancer Treatment System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
(Date:2/22/2017)... , Feb. 22, 2017  Tri-Source Pharma announced ... efforts. A series of newly appointed positions were added ... and CEO, Robert DiCrisci , in the implementation ... and management of the recently consolidated subsidiary companies. ... executive team will be composed of the following eight ...
(Date:2/22/2017)... , February 22, 2017 ... Composite, the Dow Jones Industrial Average, and the ... Seven out of nine sectors ended Tuesday,s trading ... market sentiment, Stock-Callers.com assessed the following Medical Instruments ... Inc. (NASDAQ: TNDM), C. R. Bard Inc. (NYSE: ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... , ... A product of digesting a micronutrient found in soy may hold ... soy foods, while others do not, a University of Pittsburgh Graduate School of Public ... made by some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Pet obesity in ... 54% of dogs, according to the Association for Pet Obesity Prevention (APOP). During the ... pet food issues such as the benefits of corn and grains, value of raw ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Safety, patient advocates stress that the patient context (age, illness and life choices) ... reasons to mitigate their occurrence. In addition, all too often, studies ...
(Date:2/21/2017)... Okla. (PRWEB) , ... February 21, 2017 , ... ... new Choctaw Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , ... by clinic tours for community members, clinic employees, the construction team and tribal ...
(Date:2/21/2017)... ... ... Individuals who have been diagnosed with cancer are at ... management. Regular exercise in proper environments has been shown to benefit these patients, ... 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx webinar led by ...
Breaking Medicine News(10 mins):